Immune Design is a late-stage immunotherapy company. The company is focused on oncology and has designed its technologies to activate the immune system's ability to create tumor-specific cytotoxic T cells to fight cancer via distinct mechanisms. The company's primary product candidates are CMB305 and G100. CMB305 is a prime-boost cancer vaccine targeting the NY-ESO-1 tumor antigen, in which a prime called LV305 from the company's ZVex
Insiderinsights' advanced insider analytics combine statistical track records with numerous behavioral metrics to rate the significance of a firm's insider trading history in real time.
Academic studies and the experience of professionals back the common sense conclusion that the Form 4 data filed daily at the SEC is a profitable data stream to mine for investment intelligence. But most investors use commodity insider feeds that are full of noise and time-consuming to analyze, or ratings services that employ last century's simplistic insider scoring methodology.
InsiderInsights compiles Daily, Weekly, and Monthly reports that list US equities with recent insider activity, along with proprietary Company Ratings clearly indicating the Significance Level of insider sentiment. Our monthly Special Screens further combine our Ratings with various fundamental and price action criteria, to highlight the best value, growth, momentum, and short ideas coming from the executive suite.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.